2016 Medical Gas Container-Closure Rule Questions and Answers Guidance 1/17/2017 CGMP; Administrative/Procedural; Container Closure/Packaging; Drug Product Abuse-Deterrent Opioids — Evaluation and Labeling Guidance 4/2/2015 NDA (new drugs); Drug Substance/API; Drug Product; Container Closure/Packaging; Storage and Distribution; Excipient/Inactive Ingredient; ICH; Public Health Emergency Advanced Manufacturing Technologies Designation Program Guidance 12/13/2023 Emerging/Advanced Tech, Drug product, Drug Substance/API, Administrative/Procedural Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance 9/29/2017 Emerging/Advanced Technology Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products Guidance 6/25/2015 ANDA (generic drugs); NDA (new drugs); BLA (biologics) Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs Guidance 12/1/2000 ANDA (generic drugs); Drug Substance/API Analytical Procedures and Methods Validation for Drugs and Biologics Guidance 7/27/2015 ANDA (generic drugs); NDA (new drugs); BLA (biologics); Lifecyle Management ANDAs: Impurities in Drug Products Guidance 11/29/2010 Drug Product; ANDA (generic drugs); ICH; Specification and Testing ANDAs: Impurities in Drug Substances Guidance 7/15/2009 ANDA (generic drugs); Drug Substance/API ANDAs: Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information Guidance 7/9/2007 Drug Substance/API; Drug Product; ANDA (generic drugs); Specification and Testing ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions Guidance 12/2/2022 ANDA (generic drugs); DMF (drug master files); Administrative/Procedural; Drug Product; Drug Substance/API ANDAs: Stability Testing of Drug Substances and Products Guidance 6/20/2013 ANDA (generic drugs); Specification and Testing; Drug Substance/API; Drug Product ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers Guidance 5/15/2014 ANDA (generic drugs); Specification and Testing; Container Closure/Packaging; Drug Substance/API; Drug Product ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance 5/19/2021 ANDA (generic drugs); NDA (new drugs); Specification and Testing; Drug Product Assessment of Abuse Potential of Drugs Guidance 1/18/2017 NDA (new drugs); IND (investigational new drugs); Drug Substance/API; Drug Product; Storage and Distribution; ICH; Administrative/Procedural; Public Health Emergency Benefit-Risk Considerations for Product Quality Assessments Guidance 5/9/2022 NDA (new drugs); BLA (biologics); ANDA (generic drugs); Drug Product; Drug Substance/API; Lifecycle Management Best Practices in Developing Proprietary Names for Human Prescription Drug Products Guidance 12/8/2020 Administrative/Procedural; Drug Product; Container Closure/Packaging Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action Guidance 4/3/2003 Specification and Testing; Biopharmaceutics; Lifecycle Management; Drug Substance/API; NDA (new drugs); ANDA (generic drugs); Compendial Standards; Drug Product; Storage and Distribution Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations Guidance 3/18/2014 IND (investigational new drugs); NDA (new drugs); Drug Product; Lifecycle Management; Drug Substance/API; Biopharmaceutics; Storage and Distribution Botanical Drug Development Guidance 12/29/2016 IND (investigational new drugs); ANDA (generic drugs); NDA (new drugs); BLA (biologics); Drug Product Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance 1/23/2023 Drug Substance/API; IND (investigational new drugs); NDA (new drugs); Specification and Testing CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality Guidance 7/26/2023 IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs); BLA (biologics); Compendial Standards; Administrative/Procedural CGMP for Phase 1 Investigational Drugs Guidance 7/14/2008 IND (investigational new drugs); CGMP The "Deemed to be a License" Provision of the BPCI Act: Questions and Answers Guidance 3/4/2020 NDA (new drugs); BLA (biologics); Administrative/Procedural; Lifecycle Management Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products Guidance 04/1/1996 BLA (biologics); CGMP; Specification and Testing Determining Whether to Submit an ANDA or a 505(b)(2) Application Guidance 5/10/2019 NDA (new drugs); ANDA (generic drugs); Drug Product; Container Closure/Packaging; Excipient/Inactive Ingredient; Administrative/Procedural Development and Submission of Near Infrared Analytical Procedures Guidance 8/6/2021 NDA (new drugs); ANDA (generic drugs); DMF (drug master files); Drug Product; Drug Substance/API; ICH; CGMP; Lifecycle Management; Administrative/Procedural; Specification and Testing Development of New Stereoisomeric Drugs Guidance 5/1/1992 Drug Product; Drug Substance/API; CGMP Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance 8/9/2018 Specification and Testing; ANDA (generic drugs); NDA (new drugs); IND (investigational new drugs); Drug Substance/API; ICH; Biopharmaceutics Dissolution Testing of Immediate Release Solid Oral Dosage Forms Guidance 8/25/1997 Lifecycle Management; Drug Product; Biopharmaceutics; NDA (new drugs); ANDA (generic drugs); Excipient/Inactive Ingredient; Compendial Standards; ICH Drug Master Files Guidance 11/15/2019 Drug Substance/API; Administrative/Procedural; DMF (drug master files) Drug Master Files for Bulk Antibiotic Drug Substances Guidance 11/29/1999 DMF (drug master files); administrative Drug Products, Including Biological Products, that Contain Nanomaterials Guidance 4/21/2022 Drug Product; NDA (new drugs); ANDA (generic drugs); BLA (biologics); DMF (drug master files); IND (investigational new drugs); emerging/advanced tech; Specification and Testing; Drug Substance/API; Excipient/Inactive Ingredient; CGMP; Lifecycle Management; Storage and Distribution Elemental Impurities in Drug Products Guidance 8/8/2018 ICH; Compendial Standards; NDA (new drugs); ANDA (generic drugs); Administrative/Procedural; Drug Product; Compendial Standards Environmental Assessment of Human Drug and Biologics Applications Guidance 7/27/1998 NDA (new drugs); IND (investigational new drugs); BLA (biologics); Drug Product Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity Guidance 3/4/2016 IND (investigational new drugs); ANDA (generic drugs); BLA (biologics); Administrative/Procedural; Drug Product Expanded Access to Investigational Drugs for Treatment Use—Questions and Answers Guidance 6/3/2016 IND (investigational new drugs); Drug Product; Administrative/Procedural Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron Guidance 6/9/1997 Specification and Testing; Storage and Distribution Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products Guidance 7/29/2020 CGMP; Specification and Testing; Storage and Distribution Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations Guidance 9/1/1997 Lifecycle Management; NDA (new drugs); ANDA (generic drugs); Specification and Testing; Drug Product; Excipient/Inactive Ingredient; Compendial Standards Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles Guidance 4/24/2019 Public Health Emergency; CGMP; Drug Product; Storage and Distribution Facility Readiness: Goal Date Decisions Under GDUFA Guidance 10/3/2022 ANDA (generic drugs); CGMP; Administrative/Procedural FDA Oversight of PET Drug Products Questions and Answers Guidance 12/3/2012 Drug Product; ICH; CGMP; Administrative/Procedural; Specification and Testing; Container Closure/Packaging Field Alert Report Submission: Questions and Answers Guidance 7/22/2021 NDA (new drugs); ANDA (generic drugs); Specification and Testing; Drug Product Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of HIV-1 Under PEPFAR Guidance 8/2/2023 Drug Product; Biopharmaceutics; Specification and Testing; Lifecycle Management; Administrative/Procedural Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP Guidance 1/11/2006 CGMP; Administrative/Procedural Format and Content for the CMC Section of an Annual Report Guidance 9/1/1994 NDA (new drugs); ANDA (generic drugs); Lifecycle Management; emerging/advanced tech General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance 11/21/17 ANDA (generic drugs); Specification and Testing; Drug Product Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4 Guidance 3/31/2013 NDA (new drugs); ANDA (generic drugs); BLA (biologics); IND (investigational new drugs); Drug Product; Container Closure/Packaging; Storage and Distribution Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance 7/10/2019 DMF (drug master files); Compendial Standards; Drug Product; Specification and Testing Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality Guidance 6/25/2013 CGMP; Drug Substance/API; Drug Product; Compendial Standards; Specification and Testing; ICH ICH Q12: Implementation Considerations for FDA-Regulated Products Guidance 5/20/2021 ICH; Lifecycle Management; CGMP; NDA (new drugs); ANDA (generic drugs); BLA (biologics) Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers Guidance 10/22/2019 NDA (new drugs); ANDA (generic drugs); BLA (biologics); Administrative/Procedural Immunogenicity Assessment for Therapeutic Protein Products Guidance 8/14/2014 BLA (biologics); IND (investigational new drugs); Drug Product; Container Closure/Packaging; Storage and Distribution Immunogenicity Testing of Therapeutic Protein Products—Developing and Validating Assays for Anti-Drug Antibody Detection Guidance 2/19/2019 IND (investigational new drugs); CGMP Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance 2/18/2016 ANDA (generic drugs); NDA (new drugs); DMF (drug master files); Lifecycle Management Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting Guidance 10/11/2011 NDA (new drugs); ANDA (generic drugs); Drug Product; Lifecycle Management IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations Guidance 12/8/2021 IND (investigational new drugs); Drug Product INDs for Phase 2 and Phase 3 Studies: Chemistry, Manufacturing, and Controls Information Guidance 5/20/2003 Drug Substance/API; Drug Product; IND (investigational new drugs); CGMP Inspection of Injectable Products for Visible Particulates Guidance 12/16/2021 Drug Product; CGMP; Compendial Standards; Container Closure/Packaging; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Specification and Testing; Lifecycle Management Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance 6/10/2016 BLA (biologics); IND (investigational new drugs); Drug Substance/API; Drug Product; Container Closure/Packaging; Compounding; Storage and Distribution Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance 6/10/2016 BLA (biologics); IND (investigational new drugs); Drug Substance/API; Drug Product; Container Closure/Packaging; Compounding; Storage and Distribution Interpretation of the "Deemed to be a License" Provision of the Biologics Price Competition and Innovation Act of 2009 Guidance 12/12/2018 Administrative/Procedural; Lifecycle Management Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production Guidance 5/16/2022 Specification and Testing; CGMP; Administrative/Procedural Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs Guidance 12/3/2012 IND (investigational new drugs); Specification and Testing; Drug Product; NDA (new drugs); CGMP; ANDA (generic drugs); Specification and Testing; Compendial Standards; DMF; Container Closure/Packaging; Drug Substance/API; Storage and Distribution Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators Guidance 5/15/2015 IND (investigational new drugs); Drug Product; Administrative/Procedural; Specification and Testing; Container Closure/Packaging; Storage and Distribution Labeling for Biosimilar Products Guidance 7/18/2018 BLA (biologics); Administrative/Procedural Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products Guidance 12/6/2012 IND (investigational new drugs); NDA (new drugs); BLA (biologics); ANDA (generic drugs); Drug Product; excipients/inactive ingredients Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance 4/5/2018 NDA (new drugs); ANDA (generic drugs); Administrative/Procedural; Drug Product; Biopharmaceutics Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography Guidance 4/11/2012 CGMP; Specification and Testing; Microbiology Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products—Quality Considerations Guidance 4/19/2018 Drug Product; Container Closure/Packaging; Storage and Distribution; Specification and Testing; Compendial Standards; Microbiology Microbiological Quality Considerations in Non-sterile Drug Manufacturing Guidance 9/29/2021 CGMP; Microbiology; NDA (new drugs); ANDA (generic drugs); Drug Product; Drug Substance/API; Lifecycle Management; Compendial Standards; Specification and Testing; Container Closure/Packaging; Storage and Distribution; Administrative/Procedural Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application Guidance 1/18/2018 BLA (biologics); Drug Substance/API; Drug Product; CGMP; Container Closure/Packaging; Compounding; Storage and Distribution; Excipient/Inactive Ingredient Monoclonal Antibodies Used as Reagents in Drug Manufacturing Guidance 3/1/2001 NDA (new drugs); ANDA (generic drugs); BLA (biologics); IND (investigational new drugs); Drug Substance/API; Microbiology Naming of Drug Products Containing Salt Drug Substances Guidance 6/17/2015 Drug Product; Drug Substance/API; Compendial Standards; NDA (new drugs); ANDA (generic drugs); Administrative/Procedural Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation Guidance 7/5/2002 Specification and Testing; Drug Product; Compendial Standards NDAs: Impurities in Drug Substances Guidance 2/1/2000 NDA (new drugs); Drug Substance/API; Specification and Testing; ICH; Compendial Standards Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination Guidance 4/17/2013 CGMP; Drug Substance/API; ICH; Storage and Distribution Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination Guidance 6/24/2022 CGMP; Drug Product; Drug Substance/API; Lifecycle Management; Specification and Testing Nonproprietary Naming of Biological Products Guidance 1/17/2017 BLA (biologics); Administrative/Procedural Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations Guidance 6/2/2021 Specification and Testing; Drug Product; NDA (new drugs); ANDA (generic drugs); IND (investigational new drugs) Orally Disintegrating Tablets Guidance 12/16/2008 ANDA (generic drugs); NDA (new drugs); Drug Product; Specification and Testing; Compendial Standards PAC-ATLS: Postapproval Changes—Analytical Testing Laboratory Sites Guidance 4/28/1998 NDA (new drugs); ANDA (generic drugs); Lifecycle Management PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance Guidance 10/4/2004 CGMP; NDA (new drugs); ANDA (generic drugs); BLA (biologics) PET Drug Applications—Content and Format for NDAs and ANDAs Guidance 8/31/2011 Administrative/Procedural; Drug Product; Specification and Testing; Compendial Standards; CGMP; ICH PET Drug Products—Current Good Manufacturing Practice (CGMP) Guidance 12/10/2009 CGMP; Drug Product Pharmaceutical Components at Risk for Melamine Contamination Guidance 8/6/2009 Drug Substance/API; Drug Product; CGMP; Specification and Testing; Excipient/Inactive Ingredient Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products Guidance 3/15/2011 Public Health Emergency; Administrative/Procedural; Drug Product; CGMP Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use Guidance 2/28/1997 CGMP; Microbiology, Drug Product; Specification and Testing; Container Closure/Packaging; Storage and Distribution Postapproval Changes to Drug Substances Guidance 9/11/2018 ANDA (generic drugs); NDA (new drugs); DMF (drug master files); Drug Substance/API; Lifecycle Management Potassium Iodide Tablets—Shelf Life Extension Guidance 3/08/2004 Public Health Emergency; Drug Product; Specification and Testing; Storage and Distribution; Biopharmaceutics; Compendial Standards Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens Guidance 3/1/2023 IND (investigational new drugs); BLA (biologics); Specification and Testing Preparation of Investigational New Drug Products (Human and Animal) Guidance 11/1/1992 CGMP; NDA (new drugs); ANDA (generic drugs); BLA (biologics) Process Validation: General Principles and Practices Guidance 1/25/2011 CGMP; ICH; Specification and Testing; Drug Product; Drug Substance/API Pyrogen and Endotoxins Testing: Questions and Answers Guidance 6/1/2012 CGMP; Specification and Testing; Microbiology; Compendial Standards Q&A on CGMP Requirements Guidance 9/15/2022 Container Closure/Packaging; CGMP; Storage and Distribution; Administrative/Procedural; Specification and Testing Q1A(R2) Stability Testing of New Drug Substances and Products Guidance 11/21/2003 ANDA (generic drugs); ICH; Specification and Testing; NDA (new drugs); Drug Substance/API; Drug Product; Storage and Distribution; Container Closure/Packaging; Microbiology; Biopharmaceutics Q1B Photostability Testing of New Drug Substances and Products Guidance 3/7/1996 ICH; Specification and Testing; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Container Closure/Packaging Q1C Stability Testing for New Dosage Forms Guidance 5/9/1997 ICH; Specification and Testing; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Storage and Distribution; Container Closure/Packaging Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products Guidance 1/16/2003 ICH; Specification and Testing; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Storage and Distribution; Container Closure/Packaging Q1E Evaluation of Stability Data Guidance 6/8/2004 ICH; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Storage and Distribution; Specification and Testing; Container Closure/Packaging; Biopharmaceutics Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance 9/16/2021 ICH; Specification and Testing Q3A Impurities in New Drug Substances Guidance 6/6/2008 ICH; Drug Substance/API; NDA (new drugs); ANDA (generic drugs); Specification and Testing; Storage and Distribution; CGMP Q3B(R2) Impurities in New Drug Products Guidance 8/4/2006 ICH; NDA (new drugs); ANDA (generic drugs); Drug Product; Excipient/Inactive Ingredient; Container Closure/Packaging; Specification and Testing; Storage and Distribution; CGMP Q3C Impurities: Residual Solvents Guidance 12/24/1997 ICH; Specification and Testing, NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Excipient/Inactive Ingredient Q3C—Tables and List Guidance 8/1/2018 ICH; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Excipient/Inactive Ingredient Q3D(R2) Elemental Impurities Guidance 9/14/2022 ICH; NDA (new drugs); ANDA (generic drugs); Drug Product; Specification and Testing; CGMP; Container Closure/Packaging; Excipient/Inactive Ingredient Q4B Annex 10(R1): Polyacrylamide Gel Electrophoresis General Chapter Guidance 9/2/2010 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 11: Capillary Electrophoresis General Chapter Guidance 9/3/2010 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 12: Analytical Sieving General Chapter Guidance 9/2/2010 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 13: Bulk Density and Tapped Density of Powders General Chapter Guidance 5/28/2013 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 14: Bacterial Endotoxins Test General Chapter Guidance 10/23/2013 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 2(R1): Test for Extractable Volume of Parenteral Preparations General Chapter Guidance 9/18/2017 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Drug Product; Specification and Testing Q4B Annex 3(R1): Test for Particulate Contamination: Subvisible Particles General Chapter Guidance 1/9/2009 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Drug Product; Specification and Testing; CGMP Q4B Annex 4A(R1): Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests General Chapter Guidance 4/8/2009 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing; Microbiology; Drug Product Q4B Annex 4B(R1): Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms General Chapter Guidance 4/8/2009 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing; Microbiology; Drug Product Q4B Annex 4C(R1): Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter Guidance 4/8/2009 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing; Microbiology; Drug Product; Drug Substance/API Q4B Annex 5(R1): Disintegration Test General Chapter Guidance 12/23/2009 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing; Drug Product Q4B Annex 6: Uniformity of Dosage Units General Chapter Guidance 6/16/2014 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 7(R2): Dissolution Test General Chapter Guidance 6/24/2011 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing; CGMP Q4B Annex 8(R1): Sterility Test General Chapter Guidance 12/22/2009 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Annex 9(R1): Tablet Friability General Chapter Guidance 4/5/2010 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing; Drug Product Q4B Annex I(R1): Residue on Ignition/Sulphated Ash General Chapter Guidance 2/21/2008 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Guidance 2/20/2008 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Compendial Standards; Specification and Testing Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin Guidance 11/10/2022 ICH; Specification and Testing; BLA (biologics); Drug Substance/API; Drug Product; CGMP Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products Guidance 2/23/1996 ICH; Specification and Testing; BLA (biologics) Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products Guidance 7/1/1996 ICH; Specification and Testing; BLA (biologics); Drug Substance/API; Drug Product; Excipient/Inactive Ingredient; Storage and Distribution; Container Closure/Packaging Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products Guidance 9/21/1998 ICH; Specification and Testing; BLA (biologics); Drug Substance/API; Drug Product Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process Guidance 6/30/2005 ICH; BLA (biologics); Drug Substance/API; Drug Product; Lifecycle Management; Specification and Testing; CGMP Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Guidance 12/29/2000 ICH; Specification and Testing; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Compendial Standards; CGMP; Microbiology Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Guidance 8/18/1999 ICH; Specification and Testing; BLA (biologics); Drug Substance/API; Drug Product; Compendial Standards; CGMP Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance 9/30/2016 ICH; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Drug Substance/API; CGMP; Container Closure/Packaging; Specification and Testing; Storage and Distribution; Microbiology Q8(R2) Pharmaceutical Development Guidance 11/20/2009 ICH; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Administrative/Procedural; Drug Product; Drug Substance/API; Excipient/Inactive Ingredient; Container Closure/Packaging; Microbiology; Specification and Testing; CGMP Q9(R1) Quality Risk Management Guidance 5/3/2023 ICH; Drug Product; Drug Substance/API; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Excipient/Inactive Ingredient; Container Closure/Packaging; Storage and Distribution; Specification and Testing; CGMP Q10 Pharmaceutical Quality System Guidance 4/8/2009 ICH; CGMP; Drug Substance/API; Drug Product; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Container Closure/Packaging; Storage and Distribution Q11 Development and Manufacture of Drug Substances Guidance 11/20/2012 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Drug Substance/API; Administrative/Procedural; Specification and Testing; Microbiology; CGMP Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)—Questions and Answers Guidance 2/26/2018 NDA (new drugs); ANDA (generic drugs); BLA (biologics); ICH; Drug Substance/API; CGMP; Specification and Testing; Administrative/Procedural Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance 5/11/2021 Lifecycle Management; ICH; NDA (new drugs); ANDA (generic drugs); BLA (biologics) Q13 Continuous Manufacturing of Drug Substances and Drug Products Guidance 3/1/2023 ICH; emerging/advanced tech; Drug Substance/API; Drug Product; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Lifecycle Management; CGMP Quality Attribute Considerations for Chewable Tablets Guidance 8/21/2018 Drug Product; Administrative/Procedural; NDA (new drugs); ANDA (generic drugs); IND (investigational new drugs); Compendial Standards Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance 4/30/2015 IND (investigational new drugs); BLA (biologics); ICH; Specification and Testing; Drug Product; Excipient/Inactive Ingredient; Drug Substance/API; Storage and Distribution Quality Systems Approach to Pharmaceutical CGMP Regulations Guidance 10/2/2006 ICH; CGMP; Drug Substance/API; Drug Product; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Container Closure/Packaging; Storage and Distribution Questions and Answers on Quality Related Controlled Correspondence Guidance 9/20/2021 ANDA (generic drugs); DMF (drug master files); Drug Product; Drug Substance/API; Microbiology; Container Closure/Packaging; Compendial Standards; Specification and Testing; Biopharmaceutics Referencing Approved Drug Products in ANDA Submissions Guidance 10/27/2020 ANDA (generic drugs); Specification and Testing; Drug Product Regulatory Classification of Pharmaceutical Co-Crystals Guidance 2/15/2018 NDA (new drugs); ANDA (generic drugs); Administrative/Procedural; Drug Substance/API Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities Guidance 10/25/2023 NDA (new drugs); ANDA (generic drugs); BLA (biologics); CGMP Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities Guidance 1/13/2017 Drug Product; CGMP; Container Closure/Packaging; Compounding; Storage and Distribution Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide Guidance 10/29/2021 BLA (biologics); NDA (new drugs); Drug Product; Drug Substance/API Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 Guidance 2/16/2006 Specification and Testing; Lifecycle Management; Administrative/Procedural Residual Drug in Transdermal and Related Drug Delivery Systems Guidance 8/17/2011 IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs); Drug Product; Lifecycle Management Residual Solvents in Drug Products Marketed in the United States Guidance 11/25/2009 NDA (new drugs); ANDA (generic drugs); Drug Product; Compendial Standards; ICH Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA Guidance 10/3/2022 DMF (drug master files); ANDA (generic drugs); Drug Substance/API; Administrative/Procedural Reviewer Guidance, Validation of Chromatographic Methods Guidance 11/1/1994 Drug Substance/API; Drug Product; Lifecycle Management Risk Management Plans To Mitigate the Potential for Drug Shortages Guidance 5/19/2022 CGMP; Drug Product; Drug Substance/API; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Lifecycle Management; Public Health Emergency; Storage and Distribution Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance 4/28/2015 BLA (biologics); Drug Product; Specification and Testing; Lifecycle Management; Drug Substance/API; Storage and Distribution Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use Guidance 10/3/2018 NDA (new drugs); ANDA (generic drugs); BLA (biologics); Container Closure/Packaging; Drug Product; Administrative/Procedural Size of Beads in Drug Products Labeled for Sprinkle Guidance 5/16/2012 ANDA (generic drugs); NDA (new drugs); BLA (biologics); Drug Product Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules Guidance 10/3/2022 ANDA (generic drugs); Drug Product Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999 Guidance 4/11/2003 Container Closure/Packaging Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice Guidance 10/4/2004 CGMP; Microbiology Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Guidance 11/1/1994 NDA (new drugs); ANDA (generic drugs); BLA (biologics); CGMP; Storage and Distribution; Specification and Testing; Microbiology; Container Closure/Packaging; Drug Product Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes Guidance 2/26/2010 CGMP; Storage and Distribution; Specification and Testing; Microbiology; Container Closure/Packaging; Drug Product SUPAC: Manufacturing Equipment Addendum Guidance 12/2/2014 NDA (new drugs); ANDA (generic drugs); Lifecycle Management SUPAC-IR Questions and Answers about SUPAC-IR Guidance Guidance 2/18/1997 NDA (new drugs); ANDA (generic drugs); Lifecycle Management; Biopharmaceutics; Specification and Testing; Excipient/Inactive Ingredient SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation Guidance 11/1/1995 NDA (new drugs); ANDA (generic drugs); Lifecycle Management; Biopharmaceutics; Specification and Testing; Excipient/Inactive Ingredient SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation Guidance 10/6/1997 NDA (new drugs); ANDA (generic drugs); Lifecycle Management; Biopharmaceutics; Specification and Testing; Excipient/Inactive Ingredient SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation Guidance 5/1/1997 NDA (new drugs); ANDA (generic drugs); Lifecycle Management; Biopharmaceutics; Specification and Testing; Excipient/Inactive Ingredient Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation Guidance 3/13/2013 ANDA (generic drugs); Drug Product; Lifecycle Management; Specification and Testing Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products Guidance 6/7/2013 ANDA (generic drugs); NDA (new drugs); IND (investigational new drugs); BLA (biologics); Drug Product; Specification and Testing Testing of Glycerin for Diethylene Glycol Guidance 5/8/2023 Excipient/Inactive Ingredient; CGMP; Compendial Standards The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2—Current Good Manufacturing Practice (CGMP) Guidance 1/27/2010 Biopharmaceutics; Compendial Standards; CGMP; Drug Product; Specification and Testing The Use of Physiologically Based Pharmacokinetic Analyses—Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls Guidance 9/30/2020 Biopharmaceutics; ANDA (generic drugs); NDA (new drugs); IND (investigational new drugs); Drug Product; Lifecycle Management Transdermal and Topical Delivery Systems - Product Development and Quality Considerations Guidance 11/21/2019 NDA (new drugs); ANDA (generic drugs); Drug Product; Specification and Testing Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance 10/29/2019 DMF (drug master files); Drug Product; Administrative/Procedural Use of Liquids and/or Soft Foods as Vehicles for Drug Administration: General Considerations for Selection and In Vitro Methods for Product Quality Assessments Guidance 7/25/2018 Drug Product; Compendial Standards; Specification and Testing; Biopharmaceutics Using the Inactive Ingredient Database Guidance 7/11/2019 NDA (new drugs); ANDA (generic drugs); Administrative/Procedural; Drug Product; Excipient/Inactive Ingredient Preapproval Inspections (7346.832) Compliance Program 10/17/2022 CGMP; Drug Product; Drug Substance/API; ICH; DMF (drug master files); ANDA (generic drugs); NDA (new drugs); Specification and Testing; Microbiology; Excipient/Inactive Ingredient; Compendial Standards; Container Closure/Packaging; lifecycle managament; Storage and Distribution Inspections of CDER-Led or CDRH-Led Combination Products (7356.000) Compliance Program 6/4/2020 CGMP; NDA (new drugs); ANDA (generic drugs); BLA (biologics) Drug Manufacturing Inspections (7356.002) Compliance Program 10/17/2022 CGMP; Drug Product; Drug Substance/API; ICH; ANDA (generic drugs); NDA (new drugs); Specification and Testing; Microbiology; Excipient/Inactive Ingredient; Compendial Standards; Container Closure/Packaging; Storage and Distribution; lifecycle managament Sterile Drug Process Inspections (7356.002A) Compliance Program 9/11/2015 NDA (new drugs); ANDA (generic drugs); BLA (biologics); CGMP; Microbiology; Drug Substance/API; Drug Product; Container Closure/Packaging Drug Repackagers and Relabelers (7356.002B) Compliance Program 9/11/2015 CGMP; Container Closure/Packaging; NDA (new drugs); ANDA (generic drugs); Drug Substance/API; Drug Product; Specification and Testing; Compendial Standards Radioactive Drugs (7356.002C) Compliance Program 9/11/2015 CGMP; NDA (new drugs); ANDA (generic drugs); BLA (biologics); Specification and Testing; Microbiology; Drug Product; Excipient/Inactive Ingredient; Compendial Standards; Container Closure/Packaging Compressed Medical Gases (7356.002E) Compliance Program 3/15/2015 CGMP Active Pharmaceutical Ingredient (API) Process Inspection (7356.002F) Compliance Program 9/11/2015 CGMP; Drug Substance/API; ICH; DMF (drug master files); ANDA (generic drugs); NDA (new drugs); Container Closure/Packaging; Specification and Testing; ICH Surveillance Inspections of Protein Drug Substance Manufacturers (7356.002M) Compliance Program 10/1/2021 CGMP; Drug Substance/API; ICH; BLA (biologics); Container Closure/Packaging; Specification and Testing; Microbiology; Excipient/Inactive Ingredient; lifecycle managament Positron Emission Tomography (PET) CGMP Drug Process and Pre-Approval Inspections/Investigations (7356.002P) Compliance Program 9/11/2015 Drug Product; Specificaton and Testing; CGMP; Drug Substance/API; IND (investigational new drugs); ANDA (generic drugs); NDA (new drugs); Container Closure/Packaging; Microbiology; Compendial Standards; Storage and Distribution; lifecycle managament Drug Quality Sampling and Testing (DQST)—Human Drugs (7356.008) Compliance Program 9/11/2015 Drug Product; Specification and Testing; CGMP; Drug Substance/API; ANDA (generic drugs); NDA (new drugs); Microbiology; Compendial Standards Drug Quality Reporting System (DQRS) (MedWatch Reports); NDA Field Alert Reports (FARs) (7356.021) Compliance Program 9/11/2015 Drug Product; Specification and Testing; Drug Substance/API; ANDA (generic drugs); NDA (new drugs); Microbiology; Compendial Standards Postapproval Inspections (7356.843) Compliance Program 3/13/2023 NDA (new drugs); ANDA (generic drugs); DMF (drug master files); Drug Product; Drug Substance/API; CGMP; Lifecycle Management; Specification and Testing; Storage and Distribution MAPP 5021.2 Evaluating Color Additives and Flavors Intended for Oral Drug Products Submitted or Referenced in INDs and NDAs MAPP 6/21/2023 NDA (new drugs); IND (investigational new drugs); DMF (drug master files); Drug Product; Excipient/Inactive Ingredient MAPP 5016.3 Rev. 1 Responsibility for the Quality Assessment of Products Containing Peptide or Protein Drug Substances MAPP 6/21/2023 NDA (new drugs); ANDA (generic drugs); BLA (biologics); IND (investigational new drugs); Drug Substance/API; Drug Product; Excipient/Inactive Ingredient MAPP 5021.1 Rev. 1 Naming of Drug Products Containing Salt Drug Substances MAPP 12/2/2022 NDA (new drugs); ANDA (generic drugs); IND (investigational new drugs); Drug Substance/API; Drug Product; Container Closure/Packaging MAPP 5001.1 Drug Product Distribution After a Complete Response Action to a Changes Being Effected Supplement MAPP 11/23/2022 NDA (new drugs); ANDA (generic drugs); BLA (biologics); Drug Substance/API; Drug Product; Lifecycle Management MAPP 5040.1 Product Quality Microbiology Information in the Common Technical Document - Quality (CTD-Q) MAPP 12/7/2022 NDA (new drugs); ANDA (generic drugs); BLA (biologics); Drug Product; Container Closure/Packaging; Specification and Testing; Storage and Distribution; Drug Substance/API; Microbiology; ICH; Administrative/Procedural MAPP 5210.9 Rev. 1 Review of Botanical Drug Products MAPP 12/30/2016 NDA (new drugs); IND (investigational new drugs); Drug Substance/API; Drug Product; Lifecycle Management; Specification and Testing; Biopharmaceutics; Microbiology MAPP 5019.1 Rev. 1 Allowable Excess Volume/Content in Injectable Drug and Biological Products MAPP 1/28/2022 NDA (new drugs); ANDA (generic drugs); IND (investigational new drugs); BLA (biologics); Drug Product; Container Closure/Packaging MAPP 5017.1 Rev. 1 Office of Biotechnology Products and Office of Pharmaceutical Manufacturing Assessment, Interactions on BLA Assessments MAPP 12/2/2022 BLA (biologics); IND (investigational new drugs); Drug Substance/API; Drug Product; Specification and Testing; Administrative/Procedural MAPP 5015.8 Acceptance Criteria for Residual Solvents MAPP 12/1/2022 Drug Substance/API; Drug Product; Specification and Testing; Excipient/Inactive Ingredient; ICH MAPP 5018.2 NDA Classification Codes MAPP 12/08/2022 Drug Product; IND (investigational new drugs); NDA (new drugs); Drug Substance/API; Administrative/Procedural MAPP 5016.6 Change in Hard Gelatin Capsule Supplier MAPP 2/21/2023 NDA (new drugs); ANDA (generic drugs); Lifecycle Management; Compendial Standards MAPP 5016.1 Applying ICH Q8(R2), Q9, and Q10 Principles to Chemistry, Manufacturing, and Controls Review MAPP 5/18/2016 ICH; NDA (new drugs); ANDA (generic drugs); BLA (biologics); IND (investigational new drugs); Drug Substance/API; Drug Product; Excipient/Inactive Ingredient; Lifecycle Management MAPP 5310.3 Rev. 2 Requests for Expedited Review of New Drug Application and Biologics License Application Prior Approval Supplements Submitted for Chemistry, Manufacturing, and Controls Changes MAPP 4/8/2021 NDA (new drugs); ANDA (generic drugs); BLA (biologics); Drug Product; Lifecycle Management; Public Health Emergency MAPP 5017.2 Rev. 1 Establishing Impurity Acceptance Criteria As Part of Specifications for NDAs, ANDAs, and BLAs Based on Clinical Relevance MAPP 5/1/2020 IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs); BLA (biologics); Drug Product; Specification and Testing; ICH; Compendial Standards MAPP 5015.5 Rev. 1 CMC Reviews of Type III DMFs for Packaging Materials MAPP 12/9/2022 DMF (drug master files); Compendial Standards; Lifecycle Management; Drug Substance/API; Drug Product; Container Closure/Packaging; Specification and Testing; NDA (new drugs); ANDA (generic drugs); BLA (biologics); IND (investigational new drugs) MAPP 5022.0 CDER Liaisons to Official Compendia and Standards Development Organizations – Selection Process, Roles, and Responsibilities MAPP 12/7/2022 Compendial Standards; Administrative/Procedural MAPP 5015.7 Rev. 1 Environmental Assessments and Claims of Categorical Exclusion MAPP 11/23/2022 Lifecycle Management; Drug Substance/API; IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs); BLA (biologics) MAPP 5014.1 Rev. 1 Understanding CDER's Risk-Based Site Selection Model MAPP 6/26/2023 CGMP; Drug Substance/API; Drug Product MAPP 5015.6 Rev. 1 Review of Grouped Product Quality Supplements MAPP 12/9/2022 Lifecycle Management; NDA (new drugs); ANDA (generic drugs); BLA (biologics) MAPP 5040.1 Product Quality Microbiology Information in the Common Technical Document - Quality (CTD-Q) MAPP 12/7/2022 Microbiology; Specification and Testing; ANDA (generic drugs); BLA (biologics); ICH; Container Closure/Packaging; Lifecyle Management; NDA (new drugs); Drug Substance/API; Storage and Distribution MAPP 5310.7 Rev 1 Acceptability of Standards from Alternative Compendia (BP/EP/JP) MAPP 12/8/2022 Excipient/Inactive Ingredient; Drug Substance/API; Drug Product; IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs); Specification and Testing; Compendial Standards MAPP 5017.4 Quality Center for Drug Evaluation and Research Biopharmaceutics Council MAPP 5/16/2019 Excipient/Inactive Ingredient; Drug Product; Biopharmaceutics; IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs) MAPP 5019.2 Assessment of the Appropriate Net Container Content for Injectable Drug and Biological Products MAPP 6/6/2022 NDA (new drugs); BLA (biologics); Drug Product; ANDA (generic drugs); IND (investigational new drugs); Container Closure/Packaging MAPP 5015.12 Process for Evaluating Emerging Technologies Related to Quality MAPP 12/1/2022 IND (investigational new drugs); NDA (new drugs); ANDA (generic drugs); BLA (biologics); DMF (drug master files); emerging/advanced tech MAPP 5015.13 Quality Assessment for Products in Expedited Programs MAPP 12/7/2022 NDA (new drugs); BLA (biologics); IND (investigational new drugs); Drug Product; Drug Substance/API; Public Health Emergency; Specification and Testing; Storage and Distribution; Container Closure/Packaging; CGMP Changes to an Approved NDA or ANDA  Guidance 4/8/2004 ANDA (generic drugs); NDA (new drugs); Lifecycle Management; CGMP; Container Closure/Pacakging Changes to an Approved NDA or ANDA: Questions and Answers Guidance 1/1/2001 NDA (new drugs); ANDA (generic drugs); Lifecycle Management Changes to an Approved NDA or ANDA; Specifications—Use of Enforcement Discretion for Compendial Changes  Guidance 11/22/2004 NDA (new drugs); ANDA (generic drugs); Lifecycle Management Changes to Disposable Manufacturing Materials: Questions and Answers Guidance 7/29/2022 BLA (biologics); Lifecycle Management; CGMP; NDA (new drugs); ANDA (generic drugs); Container Closure/Packing Child-Resistant Packaging Statements in Drug Product Labeling Guidance 8/13/2019 Container Closure/Packaging; Drug Product; Administrative/Procedural; NDA (new drugs); ANDA (generic drugs); BLA (biologics) Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product Guidance 12/29/2016 BLA (biologics); Specification and Testing CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports  Guidance 12/9/2021 BLA (biologics); Administrative/Procedural CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports  Guidance 3/5/2014 ANDA (generic drugs); NDA (new drugs); Container Closure/Packaging; Lifecycle Management; Specification and Testing; Drug Product Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA Guidance 10/13/2022 NDA (new drugs); ANDA (generic drugs); BLA (biologics); DMF (drug master files); Lifecycle Management; Drug Product; Drug Substance/API; CGMP; Container Closure/Packaging; Specification and Testing Completeness Assessments for Type II API DMFs Under GDUFA Guidance 10/11/2017 ANDA (generic drugs); Drug Substance/API; Administrative/Procedural Considerations in Demonstrating Interchangeability With a Reference Product Guidance 5/10/2019 BLA (biologics); Lifecycle Management; Container Closure/Packaging; Specification and Testing Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products Guidance 2/25/2009 Container Closure/Packaging; Specification and Testing; CGMP; Drug Product Container Closure Systems for Packaging Human Drugs and Biologics Guidance 7/7/1999 Drug Product; Drug Substance/API; CGMP; Container Closure/Packaging; Drug Product; DMF (drug master files) Container Closure Systems for Packaging Human Drugs and Biologics: Questions and Answers Guidance 5/1/2002 Drug Product; Container Closure/Packaging; BLA (biologics); CGMP Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance 11/23/2016 CGMP; Storage and Distribution; Administrative/Procedural; Specification and Testing Control of Nitrosamine Impurities in Human Drugs Guidance 2/24/2021 Drug Substance/API; Drug Product; Specification and Testing; ICH; Lifecycle Management Cooperative Manufacturing Arrangements for Licensed Biologics Guidance 2/24/2021 BLA (biologics); CGMP; Container Closure/Packaging; Specification and Testing; Lifecycle Management; Storage and Distribution COVID-19 Container Closure System and Component Changes: Glass Vials and Stoppers Guidance 3/4/2021 Public Health Emergency; Container Closure/Packaging; ANDA (generic drugs); BLA (biologics); NDA (new drugs); Specification and Testing; Compendial Standards; Drug Product Current Good Manufacturing Practice for Medical Gases  Guidance 6/29/2017 CGMP; Specification and Testing; Administrative/Procedural Current Good Manufacturing Practice Requirements for Combination Products Guidance 1/11/2017 Drug Substance/API; Drug Product; CGMP; Container Closure/Packaging; Specification and Testing; Storage and Distribution; Microbiology Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance 1/22/2020 CGMP; Compounding; Drug Substance/API; Drug Product; Specification and Testing; Microbiology Data Integrity and Compliance With Drug CGMP Questions and Answers Guidance 12/13/2018 CGMP; Compounding; Drug Substance/API; Drug Product; Specification and Testing; Microbiology Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products Guidance 4/1/1996 BLA (biologics); CGMP; Specification and Testing Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications Guidance 9/22/2023 NDA (new drugs); ANDA (generics); BLA (biologics); CGMP; public health emergency Quality Considerations for Topical Ophthalmic Drug Products Guidance 10/13/2023 NDA (new drugs); ANDA (generics); BLA (biologics); Drug Product; Specification and Testing; Container Closure/Packaging; Compendial Standards MAPP 5021.5 Assessment of Facility-Based Deficiency Major-to-Minor Reclassification Requests MAPP 6/27/2023 ANDA (generics); Administrative/Procedural; CGMP MAPP 5016.8 Using Four-Part Harmony in Quality-Related Assessment Communications MAPP 9/22/2023 Administrative/Procedural; Lifecycle Management; IND (investigational new drugs); NDA (new drugs); ANDA (generics); BLA (biologics); DMF (drug master files) MAPP 5017.8 Responsibilities for the Assessment of In Vitro Testing for Oral Drug Products Administered Via Enteral Feeding Tube MAPP 9/5/2023 Drug Product; IND (investigational new drugs); NDA (new drugs); ANDA (generics); Specification and Testing; Biopharmaceutics Good ANDA Submission Practices Guidance 1/26/2022 ANDA (generics); Drug Product; Drug Substance/API; Biopharmaceutics; Microbiology; CGMP; Administrative/Procedural; DMF (drug master files); Specification and Testing MAPP 5241.3 Rev. 1 Good Abbreviated New Drug Application Assessment Practices MAPP 10/6/2023 ANDA (generics); Administrative/Procedural; Drug Product

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.